INCY Incyte Corporation

123.11
-1  -1%
Previous Close 124.54
Open 125.28
Price To book 56.07
Market Cap 23.32B
Shares 189,408,000
Volume 2,035,165
Short Ratio 2.12
Av. Daily Volume 2,658,240

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 various presentations (5) at ASCO June 3-5, 2017. Abstracts 9014, 4515, 4503, 3012, 6010.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017. Abstract 3003.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Pivotal program expected to begin in 2017.
Itacitinib (JAK1)
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic arthritis
Phase 2 expected to begin in 1H 2017.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal program to commence in 2017.
Ruxolitinib
Essential thrombocythemia
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 pivotal trial dosing initiation announced December 30, 2016.
Ruxolitinib - REACH 1
Graft versus host disease

Latest News

  1. Read This Before You Buy Biotech Stocks
  2. Is Bristol-Myers Prepping To Outdo Itself In Immuno-Oncology?
  3. Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
  4. This $26 Billion Company Is the Market's Most Overpriced Biotech Stock
  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
  6. Cramer Remix: Thanks to Apple & Samsung, this group just ...
  7. Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back
  8. Incyte Corp. – Value Analysis (NASDAQ:INCY) : April 19, 2017
  9. Wells Fargo Among 5 Stocks Insiders Are Loading Up On
  10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
  11. Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
  12. ($$) Investors bet on Incyte drug success
  13. FDA Rejects Eli Lilly, Incyte's Commercialization Application
  14. Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
  15. Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : April 18, 2017
  16. Incyte to Report First Quarter Financial Results
  17. Today's Research Reports on Biotech Stocks to Watch: Cara Therapeutics and Incyte
  18. Billion dollar drug bust
  19. The Biggest Loser: Eli Lilly Drops 4.1%
  20. Why Snyder's-Lance, Incyte, and Tenet Healthcare Slumped Today